论文部分内容阅读
慢性乙型肝炎(CHB)抗病毒治疗近年获得了较大进展,目前国产抗病毒药物种类较多,但其疗效报道差别很大。本研究采用随机区组分层设计,对4种当前认为抗乙型肝炎病毒(HBV)疗效较好的药物进行前瞻性对比研究,评价其临床疗效。1 资料与方法1.1 对象 选择155例CHB住院病人,均按1995年全国传染病与寄生虫病学术会议修订的病毒性肝炎诊断标准确诊。所有病例用药前连续2次以上检测HBsAg、HBeAg或抗-HBe、抗-HBc及HBVDNA均阳性,ALT升高1.5倍于正常值以上,抗-HCV、抗-HDV及抗-HAVIgM均阴性;肝炎病
Chronic hepatitis B (CHB) antiviral therapy has made great progress in recent years, the current domestic antiviral drugs more, but the reported effect varies widely. In this study, stratified randomized block design was used to prospectively compare 4 drugs that are currently considered to be effective against hepatitis B virus (HBV) to evaluate their clinical efficacy. 1 Materials and Methods 1.1 Object Selection 155 CHB inpatients were diagnosed according to the diagnostic criteria of viral hepatitis revised in 1995 National Conference on Infectious Diseases and Parasitic Diseases. All cases were tested for HBsAg, HBeAg or anti-HBe two or more times before treatment, anti-HBc and HBVDNA were positive, ALT increased 1.5 times above normal, anti-HCV, anti-HDV and anti-HAVIgM were negative; disease